{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:22Z","timestamp":1786119622428,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/rhu.0b013e3181efa190","type":"journal-article","created":{"date-parts":[[2010,8,28]],"date-time":"2010-08-28T07:04:28Z","timestamp":1282979068000},"page":"274-279","source":"Crossref","is-referenced-by-count":49,"title":["Tumor Necrosis Factor-Alpha Antagonist-Induced Sarcoidosis"],"prefix":"10.1097","volume":"16","author":[{"given":"Rochelle","family":"Robicheaux Clementine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Zakem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi","family":"Mallepalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lindsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Quinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210207","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccm.2008.03.014","article-title":"The immunology of sarcoidosis.","volume":"29","author":"Gerke","year":"2008","journal-title":"Clin Chest Med"},{"key":"R2-4-20210207","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/CS20060094","article-title":"Steroid-resistant sarcoidosis: is antagonism of TNF- alpha the answer?","volume":"112","author":"Denys","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"R3-4-20210207","first-page":"185","article-title":"Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis.","volume":"19","author":"Ziegenhagen","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"R4-4-20210207","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccm.2008.03.012","article-title":"Treatment of sarcoidosis.","volume":"29","author":"Baughman","year":"2008","journal-title":"Clin Chest Med"},{"key":"R5-4-20210207","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"R6-4-20210207","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1378\/chest.127.3.1064","article-title":"Treatment of sarcoidosis with infliximab.","volume":"127","author":"Doty","year":"2005","journal-title":"Chest"},{"key":"R7-4-20210207","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R8-4-20210207","first-page":"1222","article-title":"Cutaneous granulomas during infliximab therapy for spondyloarthropathy.","volume":"35","author":"Dubosc","year":"2008","journal-title":"J Rheumatol"},{"key":"R9-4-20210207","first-page":"471","article-title":"Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.","volume":"26","author":"Toussirot","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"R10-4-20210207","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2169\/internalmedicine.47.0602","article-title":"Development of sarcoidosis during etanercept therapy.","volume":"47","author":"Ishiguro","year":"2008","journal-title":"Intern Med"},{"key":"R11-4-20210207","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2007.078840","article-title":"Relapse of sarcoidosis upon treatment with etanercept.","volume":"67","author":"Louie","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R12-4-20210207","first-page":"349","article-title":"Granulomatous hepatitis associated with etanercept therapy.","volume":"35","author":"Farah","year":"2008","journal-title":"J Rheumatol"},{"key":"R13-4-20210207","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s10067-007-0594-1","article-title":"Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients.","volume":"26","author":"Verschueren","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R14-4-20210207","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1592\/phco.27.10.1446","article-title":"Pulmonary sarcoidosis associated with etanercept therapy.","volume":"27","author":"Farah","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R15-4-20210207","first-page":"648","article-title":"Sarcoid-like granulomatous disease following etanercept treatment for RA.","volume":"34","author":"Kudrin","year":"2007","journal-title":"J Rheumatol"},{"key":"R16-4-20210207","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/art.22351","article-title":"Pulmonary sarcoidosis developing during infliximab therapy.","volume":"55","author":"O'Shea","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R17-4-20210207","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/art.22238","article-title":"Development of sarcoidosis during etanercept therapy.","volume":"55","author":"Gonz\u00e1lez-L\u00f3pez","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R18-4-20210207","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.21336","article-title":"Granulomatous lung disease occurring during etanercept treatment.","volume":"53","author":"Phillips","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R19-4-20210207","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/thorax.58.3.278","article-title":"Pulmonary granulomas after tumour necrosis factor \u03b1 antagonist therapy.","volume":"58","author":"Vavricka","year":"2003","journal-title":"Thorax"},{"key":"R20-4-20210207","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1378\/chest.122.5.1858","article-title":"Lung injury linked to etanercept therapy.","volume":"122","author":"Peno-Green","year":"2002","journal-title":"Chest"},{"key":"R21-4-20210207","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.rmed.2006.06.004","article-title":"Tumor necrosis factor receptors (TNFRs) on T lymphocytes and soluble TNFRs in different clinical courses of sarcoidosis.","volume":"101","author":"Kieszko","year":"2007","journal-title":"Respir Med"},{"key":"R22-4-20210207","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1378\/chest.127.1.251","article-title":"Production of soluble tumor necrosis factor receptors and tumor necrosis factor-alpha by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis.","volume":"127","author":"Dai","year":"2005","journal-title":"Chest"},{"key":"R23-4-20210207","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1126\/science.1071924","article-title":"TNF-R1 signaling: a beautiful pathway.","volume":"296","author":"Chen","year":"2002","journal-title":"Science"},{"key":"R24-4-20210207","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.4049\/jimmunol.179.6.4239","article-title":"Interaction between transmembrane TNF and TNFR1\/2 mediates the activation of monocytes by contact with T cells.","volume":"179","author":"Rossol","year":"2007","journal-title":"J Immunol"},{"key":"R25-4-20210207","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4049\/jimmunol.176.2.1026","article-title":"TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo.","volume":"176","author":"Kim","year":"2006","journal-title":"J Immunol"},{"key":"R26-4-20210207","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4049\/jimmunol.179.1.154","article-title":"Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells.","volume":"179","author":"Chen","year":"2007","journal-title":"J Immunol"},{"key":"R27-4-20210207","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells.","volume":"203","author":"Miyara","year":"2006","journal-title":"J Exp Med"},{"key":"R28-4-20210207","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"R29-4-20210207","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.21671","article-title":"Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.","volume":"54","author":"Wolbink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R30-4-20210207","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R31-4-20210207","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00216-008-1938-7","article-title":"Off-target activity of TNF-alpha inhibitors characterized by protein biochips.","volume":"391","author":"Feyen","year":"2008","journal-title":"Anal Bioanal Chem"},{"key":"R32-4-20210207","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1164\/ajrccm\/143.1.53","article-title":"Increased levels of serum interferon-gamma I pulmonary sarcoidosis and relationship with response to corticosteroid therapy.","volume":"143","author":"Prior","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"R33-4-20210207","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor necrosis factor antagonist: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection.","volume":"36","author":"Furst","year":"2006","journal-title":"Semin Arthritis Rheum"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00124743-201009000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:35:41Z","timestamp":1786041341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00124743-201009000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e3181efa190","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}